Why pharma manufacturers are still investing in Europe
Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s…
23 Jan 2026
High-dose biologic delivery to become industry standard
As the pharmaceutical industry progresses further into the age of personalised medicine, next-generation, targeted and disease-modifying biologics are becoming increasingly commonplace across all major disease subcategories. Alongside the shift to…
21 Jan 2026
Walking the pharma supply chain tightrope requires more than precision
Between 2023 and 2025, hundreds of thousands of Type 2 diabetes patients were unable to access semaglutide due to off-label prescriptions for the drugs in individuals seeking weight loss. The…
06 Jan 2026
Podcast: Healthcare’s biggest 2025 trends and 2026 predictions
As the healthcare industry embarks on a new year, there are several factors that look set to impact pharmaceutical and medical companies. In this episode, the healthcare team analyses the…
30 Dec 2025
How one US state is tackling the drug affordability crisis
Drug affordability remains a key priority for the US government as it negotiates with pharma companies to lower individual drug prices and explore reference pricing models. With these efforts underway…
29 Dec 2025
Enriched patient data needed to uncover sex differences in Alzheimer’s trials
Researchers say that women are twice as likely to develop Alzheimer’s disease as men. However, despite recent advances in treatments for the condition, historical biases in clinical trial recruitment have…
24 Dec 2025
Alternative commercialisation models offer lifeline to future of gene therapies
Cell and gene therapies (CGTs) have captured significant interest in the pharma industry, with the modality being explored in multiple disease areas from oncology to autoimmune diseases due to their…